We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

113 hedge funds and large institutions have $809M invested in Avadel Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 34 increasing their positions, 27 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $15.6M | Put options by funds: $4.96M

175% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 8

45% more capital invested

Capital invested by funds: $559M → $809M (+$250M)

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

14% more funds holding

Funds holding: 99 → 113 (+14)

2.97% more ownership

Funds ownership: 60.85% → 63.82% (+3%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
113
Holders Change
+14
Holders Change %
+14.14%
% of All Funds
1.65%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
22
Increased
34
Reduced
27
Closed
8
Calls
$15.6M
Puts
$4.96M
Net Calls
+$10.6M
Net Calls Change
+$3.01M

Top Buyers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
+$26.3M
2
Morgan Stanley
Morgan Stanley
New York
+$18.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$9.18M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$5.72M
5
ABG
Ally Bridge Group
New York
+$4.08M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$17.6M
2
CAC
Cowen and Company
New York
-$8.18M
3
JP Morgan Chase
JP Morgan Chase
New York
-$4.75M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.14M
5
Marshall Wace
Marshall Wace
United Kingdom
-$3.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BCV
101
Banque Cantonale Vaudoise
Switzerland
$14K – – –
HFS
102
Hantz Financial Services
Michigan
$11K – – –
BWP
103
Baldwin Wealth Partners
Massachusetts
$7.06K – – –
SIC
104
Salem Investment Counselors
North Carolina
$6.35K – – –
GI
105
GAMMA Investing
California
$4.5K +$3.68K +313 New
Daiwa Securities Group
106
Daiwa Securities Group
Japan
$3K – – –
HIA
107
Harbor Investment Advisory
Maryland
$2.82K – – –
AWM
108
Able Wealth Management
New Jersey
$1.62K +$1.35K +115 New
LC
109
Lindbrook Capital
California
$1.38K – – –
PA
110
Parallel Advisors
California
$593 – – –
Barclays
111
Barclays
United Kingdom
$339 -$282 -24 -50%
S
112
SignatureFD
Georgia
$311 +$258 +22 New
HNB
113
Huntington National Bank
Ohio
$14 – – –
JGC
114
J. Goldman & Co
New York
– -$1.92M -163,382 Closed
SCM
115
Soleus Capital Management
Connecticut
– -$1.07M -104,000 Closed
SAM
116
Silverback Asset Management
North Carolina
– -$1.17M -100,000 Closed
Qube Research & Technologies (QRT)
117
Qube Research & Technologies (QRT)
United Kingdom
– -$551K -53,523 Closed
VF
118
Virtu Financial
New York
– -$206K -20,047 Closed
Squarepoint
119
Squarepoint
New York
– -$150K -14,582 Closed
Corient Private Wealth
120
Corient Private Wealth
Florida
– -$125K -12,091 Closed
QT
121
Quantbot Technologies
New York
– -$78.1K -7,587 Closed
1 2 3 4
5

AVDL Hedge Fund Activity: Q4 2023 in Review

113 of the 6,864 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2023, worth a combined $809M — up 45% from $559M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new AVDL positions and 8 closed out — a net gain of 14 holders — while 34 added to existing stakes and 27 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $26.3M. The largest seller was Adage Capital Partners, cutting an estimated $17.6M.

  • 113 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2023, up from 99 in Q3 2023.
  • Funds reported $809M of Avadel Pharmaceuticals stock for Q4 2023, up 45% quarter-over-quarter.
  • 22 funds opened new Avadel Pharmaceuticals positions in Q4 2023 and 8 closed out, a net change of +14 holders.
  • The largest Avadel Pharmaceuticals buyer in Q4 2023 was Polar Capital Holdings, an estimated $26.3M added.
  • The largest Avadel Pharmaceuticals seller in Q4 2023 was Adage Capital Partners, an estimated $17.6M sold.

Based on aggregated 13F filings for Q4 2023.